Skip to main content
padlock icon - secure page this page is secure

Open Access Multiple doses of icatibant used during pregnancy

Download Article:
 Download
(HTML 33.6 kb)
 
or
 Download
(PDF 55.6 kb)
 
Background:

Hereditary angioedema (HAE) is a life-long disease that often manifests by puberty. Treatment of attacks is essential to improve quality of life and to decrease morbidity and mortality. During pregnancy, treatment is limited because multiple treatment options, including icatibant, are not approved for use during pregnancy.

Objective:

We report the outcomes of three pregnancies during which icatibant was used by a patient with HAE with normal C1-inhibitor for treatment of attacks. We also reviewed the literature for reports of icatibant use during pregnancy for outcomes and adverse events.

Methods:

We report on a patient who treated herself with icatibant during three separate pregnancies. Postpartum follow-up verified the health of the mother and children. We also performed a complete literature search of medical literature data bases on icatibant use during pregnancy.

Results:

The patient in our report administered multiple doses of icatibant during three pregnancies. The child born from the first pregnancy and the child from the third pregnancy were born at term and without congenital anomalies. The child from the second pregnancy was 1-month preterm. All three children were developmentally normal. The literature search identified two case reports and one abstract of limited icatibant use without adverse events during pregnancy in patients with HAE. These pregnancies resulted in the births of healthy infants.

Conclusion:

From a search of the literature, three cases of icatibant use during pregnancy resulted in healthy infants. In addition, we report that from icatibant use in three separate pregnancies, one infant was born prematurely, but there were no birth defects. From follow-up, the children continued meeting developmental milestones. This report adds to the acquisition of knowledge for drug adverse events during postmarketing surveillance for icatibant use during pregnancy.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: C1-inhibitor; Hereditary angioedema; adverse events; bradykinin; decidua; gestation; icatibant; pregnancy

Document Type: Research Article

Affiliations: From the Department of Allergy, Asthma, and Immunology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania

Publication date: 01 October 2017

More about this publication?
  • Allergy and Rhinology will no longer be hosted on Ingenta Connect as of July 10, 2018. For all subscription orders where the customer's end-user address is in the USA, Canada, Central and South America including the Caribbean, please contact [email protected] For all subscription orders where the customer's end user address is in the UK, Europe, Middle East, Africa and Australasia, please contact [email protected]
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more